GlassScriptPhysician profile
John M Ransom
NPI 1477513778
$11,572.29
in general payments reported to CMS, 2019-2025
32 companies · $5,024 in 2025
The $5,024 reported for 2025 was more than what 82% of Thoracic Surgery (Cardiothoracic Vascular Surgery) providers received nationally (typical 2025 total: $796).
See the full distribution for Thoracic Surgery (Cardiothoracic Vascular Surgery)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,035 · 2020: $709 · 2021: $1,439 · 2022: $1,145 · 2023: $714 · 2024: $507 · 2025: $5,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,000 · Food and Beverage: $1,245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,000.00 |
| Food and Beverage | $1,244.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Briohealth Solutions, INC. | $5,077.03 | 2024-2025 | Briovad |
| Abbott Laboratories | $1,973.45 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Cardiomems, Thoratec Heartmate II, Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $697.94 | 2019-2024 | |
| Actelion Pharmaceuticals US, INC. | $673.89 | 2019-2023 | Uptravi, Opsumit |
| Abiomed | $559.77 | 2019-2024 | Impella |
| Alnylam Pharmaceuticals INC. | $403.10 | 2019-2024 | Onpattro, Amvuttra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $400.25 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $341.82 | 2020-2023 | Wainua |
| United Therapeutics Corporation | $248.45 | 2019-2021 | |
| Pfizer INC. | $178.18 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.66 | 2019-2023 | Lifevest |
| Amgen INC. | $153.06 | 2019-2020 | |
| Astellas Pharma US INC | $147.86 | 2019-2024 | Cresemba |
| Davol INC. | $88.16 | 2021 | |
| Sanofi-Aventis U.S. LLC | $68.21 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $67.62 | 2024 | Inpefa |
| Baxter Healthcare | $44.10 | 2019 | |
| Haemonetics Corporation | $30.11 | 2023 | Bloodtrack |
| Regeneron Healthcare Solutions, INC. | $29.91 | 2019 | |
| Livanova USA, INC. | $28.83 | 2019 | |
| Paragonix Technologies, INC. | $28.14 | 2022 | |
| Octapharma USA, INC. | $25.80 | 2020 | |
| Abbvie INC. | $21.55 | 2024 | |
| Irhythm Technologies, INC. | $19.52 | 2021 | |
| Boston Scientific Corporation | $17.32 | 2019 | |
| Novo Nordisk INC | $16.98 | 2024 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $14.75 | 2021 | |
| Akcea Therapeutics, INC. | $13.90 | 2020 | |
| Lilly USA, LLC | $12.70 | 2022 | |
| Janssen Pharmaceuticals, INC | $12.38 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $11.72 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ransom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.